Overview of Tilatil

Tilatil is a medicinal preparation that has the core purpose of providing relief from the symptoms of inflammation, pain, and fever. It contains the active pharmaceutical ingredient Tenoxicam and belongs to the powerful Non-Steroidal Anti-Inflammatory Drug (NSAID) class. Tilatil is the original brand name marketed by Roche, and its distinctive feature among many competing NSAIDs is the prolonged action offered by its active compound.

Property	Description
Active ingredient	Tenoxicam
Form	Tablets, lyophilized powder (for injection), suppositories
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose	Symptomatic relief of pain and inflammation
Origin	Synthetic compound

What Type of Medicine is Tilatil? (Identity and Classification)

Tilatil's identity is defined by its active component, Tenoxicam, a synthetic chemical categorized as an NSAID and specifically a member of the oxicam subclass. This classification signifies its mechanism of action, which involves inhibiting the production of prostaglandins—the chemical mediators that trigger inflammation, pain, and fever. The specific oxicam structure grants Tenoxicam a long elimination half-life, which typically ranges from 60 to 80 hours. This prolonged presence in the body is a key differentiating factor, making Tilatil clinically recognized for its sustained efficacy in the management of chronic symptoms where once-daily dosing is beneficial.

What is Tilatil Used for Generally? (High-Level Purpose)

The general therapeutic purpose of Tilatil is to provide symptomatic relief by broadly addressing the body's inflammatory cascade. The medicine is utilized for its capacity to suppress the three primary physiological manifestations of inflammation: to reduce swelling (anti-inflammatory effect), to alleviate discomfort (analgesic effect), and to help normalize elevated body temperature (antipyretic effect).

Clinical data confirm Tenoxicam's efficacy as an effective analgesic and anti-inflammatory agent, particularly supporting its use for the symptomatic management of various rheumatic conditions. The drug is manufactured into multiple forms—oral tablets, an injectable solution (reconstituted from powder), and suppositories—to ensure flexibility in administration based on the patient’s needs, such as providing rapid pain relief via injection.

What side effects are possible with Tilatil?

Tilatil: Possible Side Effects and Safety Information

Tilatil (Tenoxicam) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) with a safety profile primarily focused on serious gastrointestinal and cardiovascular risks, as outlined in official regulatory documents.

Adverse Reactions Summary

System-Organ Class	Common Adverse Reactions (Official)	Serious Adverse Reactions (Official)
Gastrointestinal Disorders	Dyspepsia, Nausea, Abdominal pain	Bleeding, Ulceration, and Perforation (can be fatal).
Nervous System Disorders	Headache, Dizziness	Stroke, Vision disturbances
Skin and Subcutaneous	Rash, Pruritus (itching)	Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Exfoliative Dermatitis (life-threatening cutaneous reactions).
Cardiac/Vascular Disorders	Oedema (swelling)	Increased risk of Arterial Thrombotic Events (e.g., Myocardial Infarction/Heart Attack).

Safety Considerations and Restrictions

Elderly Patients face an increased frequency and severity of adverse reactions, particularly gastrointestinal bleeding and perforation. The risk of serious cardiovascular and gastrointestinal events is generally considered to be dose- and duration-related (higher with prolonged use or high doses).

Contraindications include, but are not limited to, patients with an active peptic ulcer, active gastrointestinal bleeding or perforation, severe heart failure, severe hepatic or renal failure, or a history of hypersensitivity to tenoxicam or other NSAIDs. The drug should be immediately withdrawn if peptic ulceration or GI bleeding occurs.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Tilatil (Tenoxicam) overdosage defines the required emergency procedures rather than a list of specific clinical signs. Regulatory documentation notes that cases detailing the clinical manifestations of tenoxicam overdose have not been reported in the official labeling, meaning a defined symptom profile is not available from authoritative sources.

Scope of Overdose Information	Official Regulatory Statement
Documented Manifestations	Specific cases of overdosage have not been reported in the regulatory documentation.
Mandated Emergency Action	For management of a suspected drug overdose, contact a regional poison control centre.
Indicated Treatment	Supportive and symptomatic therapy is indicated in the event of overdosage.

Immediate Actions Required

Immediate medical assistance must be sought for the management of any suspected drug overdose involving Tilatil. The official regulatory instruction mandates that individuals contact a regional poison control centre for specialized guidance and to initiate necessary procedures. In situations of known or suspected overdosage, the treatment approach is officially defined as symptomatic and supportive therapy. The official documents do not explicitly detail specific hospital monitoring requirements or population-specific considerations (such as for the elderly or patients with renal impairment) within the overdose section. This instruction for external consultation and supportive care forms the entirety of the official, regulator-mandated overdose profile.

Therapeutic Uses of Tilatil

Tilatil (Tenoxicam) is commonly used across therapeutic domains where additional symptomatic support is needed, primarily focusing on conditions characterized by significant pain, inflammation, and stiffness. This approach provides support that helps ease the overall symptom burden. The medicine is applied in therapeutic areas involving heightened responses.

The medication is relevant for a variety of conditions presenting with acute or recurrent manifestations, including chronic diseases like Rheumatoid Arthritis and Osteoarthritis, as well as acute issues such as ankylosing spondylitis, tendinitis, bursitis, and pain following soft-tissue injuries.

It is considered relevant in contexts marked by increased discomfort arising from these acute events. One way to view its utility is that “it assists patients with coping more steadily with temporary functional strain and supports general well-being.” Applied during phases of increased distress, Tilatil may offer symptomatic relief, helping in the management of acute discomfort and providing support that contributes to easing the overall symptom load.

Quick Fact: Symptomatic Support

Feature	Therapeutic Context
Primary Focus	Inflammation, Stiffness, and Musculoskeletal Pain
Role in Chronic Scenarios	Easing of persistent symptoms in OA and RA
Acute Scenarios	Supportive relief for sprains, lumbago, and post-operative pain

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Eligibility for Tilatil (Tenoxicam), an NSAID, is strictly defined by regulatory authorities based on age, physiological status, and the presence of certain concurrent medical conditions.

Contraindicated Populations (Must NOT Use)

Category	Regulatory Status
Allergy	Contraindicated in patients with known hypersensitivity to Tenoxicam or other NSAIDs (e.g., aspirin) [Source 1.4].
GI Health	Contraindicated in patients with active gastrointestinal bleeding, ulceration, or perforation, or a history of recurrent peptic ulcers related to previous NSAID use [Source 2.1].
Organ Failure	Contraindicated in severe heart failure, severe renal impairment, or severe hepatic impairment [Source 2.1].
Late Pregnancy	Contraindicated during the third trimester of pregnancy (after 28–30 weeks gestation) [Source 3.3].

Populations Requiring Restriction or Special Caution

Category	Regulatory Status
Age (Pediatric)	Not Recommended for use in patients under 16 years of age, as dose and indications have not been established [Source 1.3].
Age (Older Adults)	Special Caution is required; the lowest effective dose for the shortest duration is mandated due to increased risk of serious adverse reactions [Source 1.4].
Pregnancy	Not Recommended during the first and second trimesters unless the benefit is determined to outweigh the risk [Source 1.4].
Lactation	Not Recommended for use while breastfeeding [Source 1.3].
Fertility	Not Recommended for women attempting to conceive, as use may impair female fertility [Source 3.1].

These restrictions ensure the medicine is only used by populations for whom the risk-benefit profile is considered acceptable under official prescribing guidelines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Officially documented interaction patterns for Tilatil (Tenoxicam) are primarily structured around pharmacokinetic (PK) and pharmacodynamic (PD) risks, as defined in regulatory labeling. The co-administration of Tilatil with other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, is formally contraindicated.

Interaction with several drug classes significantly increases the documented risk of hemorrhage. The co-administration of Tenoxicam with oral anticoagulants (such as Warfarin), anti-platelet agents, oral corticosteroids, and SSRIs/SNRIs significantly heightens the risk of gastrointestinal bleeding and ulceration.

Specific PK interactions involve altered clearance of co-administered medicines. Tenoxicam is documented to reduce the renal clearance of substances such as Lithium and Methotrexate, resulting in increased plasma concentrations and potential toxicity for those agents. Tenoxicam is metabolized via the CYP2C9 enzyme; therefore, co-administration with strong CYP2C9 inhibitors may increase its plasma exposure.

Another area of regulatory focus is on kidney function. The combination of Tilatil with Diuretics, ACE Inhibitors, or ARBs carries a documented risk of acute renal failure. This nephrotoxic interaction risk is formally stated to be increased in elderly patients and those with pre-existing conditions like heart failure or renal impairment. Tilatil also requires a time separation when co-administered with Mifepristone.

Mechanism of Action

How Tilatil Works: Pharmacodynamics

Tenoxicam acts primarily by non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and inducible COX-2 isoforms. This interaction blocks the conversion of arachidonic acid into prostanoids, significantly reducing the cellular synthesis of key chemical mediators, particularly prostaglandins. This modulation of the eicosanoid cascade reduces the chemical processes that sensitize peripheral nerve endings and alters the regulatory set-point in the hypothalamus.

Secondary mechanistic actions include the inhibition of Matrix Metalloproteinases (e.g., Stromelysin), enzymes involved in the degradation of joint cartilage components, which modulates connective tissue catabolism. The drug also functions as a scavenger of active oxygen species (free radicals), altering the activity of these highly reactive molecules released by immune cells. Concurrently, the inhibition of the constitutive COX-1 enzyme influences pathways vital for physiological maintenance, affecting TXA2 synthesis in platelets and reducing the production of prostaglandins that regulate basal physiological processes in the gastric mucosa and the renal vasculature.

Dosage and Administration Information

Tilatil (Tenoxicam) is a medicinal preparation administered through multiple approved routes: primarily oral tablets, but also via rectal suppositories and a lyophilized powder for injection. The compound's extended action dictates that the standard administration schedule is typically once daily.

Standard Administration and Dosing

The standard maintenance dose for chronic use is 20 mg taken once daily. For managing acute presentations, such as certain post-operative pain or acute gout, a higher initial dose of 40 mg is authorized for a limited short course, usually two to five days, before continuing with a lower regimen. Official administration instructions specify that oral tablets must be swallowed whole and should be taken with or after food. A core procedural principle is to administer the lowest effective dose for the shortest duration necessary to meet the required protocol.

Specialized Use and Administration Constraints

The intramuscular (IM) and intravenous (IV) routes are restricted to the initiation of treatment, with administration officially limited to a maximum of one to two days before switching to the oral or rectal form. For parenteral use, the powder must be immediately reconstituted with 2 mL of sterile water and given as a bolus injection; infusion is not recommended. Regarding specific patient groups, the label mandates the use of the lowest possible dose in older adults, and administration to children is not recommended due to insufficient data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tilatil (Tenoxicam)

This section describes the types of clinical studies that have been conducted for Tilatil (Tenoxicam), what research has explored, and where limitations or gaps remain in the scientific evidence, based on findings documented in peer-reviewed scientific literature and regulatory summaries.

Evidence for Use in Chronic Joint Conditions

Research on Tenoxicam has largely focused on conditions characterized by fluctuating or episodic manifestations of joint pain and inflammation, particularly Rheumatoid Arthritis (RA) and Osteoarthritis (OA). The clinical evaluation primarily relies on Randomized Controlled Trials (RCTs), where research examined its use against an inactive substance or against other compounds in the same class. These studies were used in research exploring how symptoms change over time.

For both RA and OA, studies explored outcomes related to physical discomfort, specifically monitoring changes in pain intensity (measured on patient scales), joint swelling, and the duration of morning stiffness. When research examined its use against other compounds, the studies monitored the patterns of measured symptomatic outcomes in the observed populations.

Evidence for Acute Pain and Musculoskeletal Issues

Tenoxicam was evaluated in studies focusing on episodes where symptoms become more noticeable, such as Ankylosing Spondylitis (AS) and acute musculoskeletal disorders like tendinitis, bursitis, and pain following procedures. For AS, short-term RCTs with relatively small sample sizes were conducted during periods of increased symptom activity. These studies monitored core disease measures like morning stiffness duration and patient-reported pain.

In the context of postoperative pain, research explored short-term symptom changes, often looking at outcomes related to episodic or acute changes in pain intensity in the hours following a procedure. However, evidence quality varies across studies, and some systematic reviews have noted that certain high-quality, placebo-controlled trials designed to evaluate single-dose oral use in acute pain models are limited.

What Remains Uncertain in the Research Record

The evidence highlights what is known — and what is still uncertain — about Tenoxicam. For some conditions like Ankylosing Spondylitis, sample sizes were modest, and follow-up durations were limited to short-term assessment. Furthermore, comparative evidence is lacking for comprehensive, head-to-head comparisons against all contemporary NSAIDs and non-pharmacological therapies used today across all indications. Research does not determine whether an individual will respond similarly to the group patterns described in the studies, and the body of work mainly describes patterns for changes in symptom intensity but offers limited insight into long-term disease modification.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tilatil (FAQ)

Q: How long does the effect of a Tilatil tablet last?

Official documents indicate that the drug has a long duration of action. The elimination half-life is the time it takes for half of the medicine to be eliminated from the body, and it typically ranges from 60 to 80 hours. This long half-life is the characteristic that allows for a standard once-daily administration schedule.

Q: What's the difference between Tilatil and other similar pain relievers?

Tilatil contains the active ingredient Tenoxicam, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its main distinguishing factor among many NSAIDs is its long elimination half-life. This property is why the medicine is often administered on a standard once-daily dosing regimen.

Q: Is it common to feel drowsy or sleepy when taking Tilatil?

Official regulatory documents list side effects such as feeling sleepy, tired, or dizzy as reported events under the nervous system category. Additionally, trouble sleeping (insomnia) and nightmares are noted in the official information as rare side effects.

Q: Can Tilatil affect my blood pressure?

Official safety information indicates that high blood pressure has been reported with drugs in this class. Fluid retention, known as oedema or swelling, has also been reported as a side effect. For populations with a history of high blood pressure, appropriate monitoring is noted in regulatory warnings.

Q: Do any official warnings exist about Tilatil and alcohol consumption?

According to the official patient information, consuming alcohol may potentially worsen some side effects of the medicine. Specifically, side effects such as dizziness or light-headedness may be more noticeable if alcohol is used concurrently.

Q: What happens if I miss a dose of Tilatil?

Official guidelines on missed doses generally state that the dose should be taken when remembered, if not close to the time for the next dose. However, if it is almost time for the next scheduled once-daily dose, the instruction is typically to skip the missed dose and continue with the regular schedule.

Q: Is there a generic version of Tilatil available?

Yes. Tilatil is a brand name medicine, and its active ingredient is Tenoxicam, which is the generic name. Tenoxicam is manufactured and sold internationally under various trade names by different companies.

Q: Does taking Tilatil make you sensitive to sunlight?

Regulatory documents indicate that a rash caused by exposure to sunlight, known as photosensitivity, is a reported side effect of the medicine. This is generally listed as a rare adverse event in official information.

Q: Does Tilatil affect the results of any common medical tests?

Official safety documents note that changes in the results of blood tests have been reported as side effects. These changes can include reduced platelet count and alterations to white or red blood cell levels.

Q: What are the official guidelines regarding stopping the use of Tilatil?

Official safety information indicates that the medicine should be immediately withdrawn if specific serious reactions occur. This includes any signs of peptic ulceration, gastrointestinal bleeding, or serious skin reactions.

Q: How do medical professionals monitor a patient while they are taking Tilatil?

Regulatory documents state that for populations on long-term treatment or those with pre-existing risk factors, careful monitoring is necessary. This monitoring may include checking renal (kidney), hepatic (liver), and cardiac (heart) function, as well as regular blood work checks.

Q: Does Tilatil affect sleep patterns?

According to official regulatory documents, sleep problems have been reported as side effects. These problems can include difficulty falling asleep (insomnia) and experiencing nightmares, and they are generally listed as rare occurrences.

Q: Are there specific instructions for what to do in case of an allergic reaction to Tilatil?

Official safety information indicates that immediate medical attention and discontinuation of the medicine are necessary if signs of a serious allergic or hypersensitivity reaction are suspected. This includes signs such as a skin rash or mucosal lesions.

Q: What does the patient information leaflet say about overdose symptoms for Tilatil?

Official documentation on overdose notes that symptoms are often an intensification of the drug's known adverse effects. These may include gastrointestinal disturbances such as nausea, vomiting, or bleeding, and central nervous system symptoms like dizziness and drowsiness.

Q: What regulatory body approved Tilatil for use in my country?

Tilatil is approved by national regulatory authorities that oversee the safe use of medicines. These bodies include agencies in the European Union member states, Canada, and other countries. Specific approvals and accepted uses may vary by country.

Q: Can Tilatil impact blood sugar levels in diabetic patients?

Regulatory documents list increased glucose in the blood as a reported, though rare, side effect of the medicine. Furthermore, populations with pre-existing conditions like diabetes mellitus are identified as requiring careful monitoring of organ function when using NSAIDs.

Q: What kind of foods or drinks should I be careful about when using Tilatil?

Oral tablets are officially recommended to be taken with or after food to help reduce the chance of stomach upset. Official warnings also suggest that consuming alcohol may potentially worsen side effects such as dizziness or light-headedness.

Q: Is Tilatil used long-term or short-term?

According to official documentation, Tilatil is used for both short-term management of acute pain and musculoskeletal disorders, and for the longer-term, symptomatic maintenance of chronic conditions. Examples of chronic conditions include Rheumatoid Arthritis and Osteoarthritis.

Q: Are there any warnings about driving or operating machinery while on Tilatil?

Official warnings state that if the drug causes side effects such as dizziness, drowsiness, or fatigue, or leads to problems with eyesight, there is a risk of impaired ability to drive or operate machinery.

Q: What does 'half-life' mean in relation to Tilatil?

The term half-life is used in official documentation to describe the time required for the amount of medicine in the body to be reduced by half. Tilatil is noted to have a long half-life, typically around 60 to 80 hours, which is the reason it is administered once daily.

How should Tilatil be stored and disposed of?

How to Store and Dispose of Tilatil (Tenoxicam)?

Tilatil must be stored according to official regulatory specifications to maintain product stability and potency. The medication should be kept out of the sight and reach of children.

Storage and Handling Requirements

Requirement	Specific Condition
Temperature	Store below 30 C (for tablets); store powder for injection below 25 C.
Protection	Must be protected from light and moisture in its original, tightly sealed container.
Stability	The reconstituted injection solution must be used immediately after preparation.
Safety	Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Tilatil must be disposed of safely and should not be thrown into household waste or wastewater. To comply with official environmental protection protocols, the product should be returned to a pharmacist for appropriate disposal.

Tilatil